Less endocrine therapy in HR+/HER2- breast cancer: a nationwide trend despite unchanged guidelines
Despite unchanged guideline recommendations, fewer patients started ET over time. This trend, and regional variation, suggests that a more reticent approach by physicians to initiating ET for HR+/HER2- breast cancer may be contributing to it.
Authors
- José H. Volders (ORCID: https://orcid.org/0000-0002-9190-4579)
- Eline E. F. Verreck (ORCID: https://orcid.org/0009-0003-4630-9214)
- Sabine Siesling
- Emily L. Postma (ORCID: https://orcid.org/0000-0001-8460-0553)
- Thijs van Dalen (ORCID: https://orcid.org/0000-0003-0882-9086)
- Anouk H. Eijkelboom (ORCID: https://orcid.org/0000-0002-0660-0221)
- Tanja Oostergo (ORCID: https://orcid.org/0009-0004-8154-9069)
- Dimitris Rizopoulos (ORCID: https://orcid.org/0000-0001-9397-0900)
- Joyce Meijer (ORCID: https://orcid.org/0000-0002-7327-5916)
Institutions
- Erasmus MC (NL)
- University Medical Center Utrecht (NL)
- St. Antonius Ziekenhuis (NL)
- Diakonessenhuis hospital (NL)
- Netherlands Comprehensive Cancer Organisation (NL)
- Erasmus University Rotterdam (NL)
Publication Details
- Journal
- The Breast
- Published
- 2025-11-27
- DOI
- https://doi.org/10.1016/j.breast.2025.104664
- Primary Topic
- Breast Cancer Treatment Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00